Physiological, pharmacological and clinical features of the multidrug resistance protein 2

被引:68
作者
Fardel, O
Jigorel, E
Le Vee, M
Payen, L
机构
[1] INSERM, Fac Pharm, U620, F-35043 Rennes, France
[2] INSERM, U590, Fac Med Rockfeller, F-69008 Lyon, France
关键词
MRP2; pharmacokinetic; drug resistance;
D O I
10.1016/j.biopha.2005.01.005
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multidrug resistance protein 2 (MRP2, ABCC2) is a drug efflux pump belonging to the ATP-binding cassette (ABC) transporter superfamily. MRP2 is present predominantly at the biliary pole of hepatocytes and is also expressed in the kidney and intestine. It plays a major role in hepato-biliary elimination of many structurally diverse xenobiotics, including organic anions and drug conjugates, and therefore most likely contributes to pharmacokinetic parameters of these compounds. MRP2 also handles endogenous molecules such as bilirubin, and its overexpression has been shown to confer a multidrug resistance phenotype to tumoral cells. MRP2 expression can be regulated by endogenous substances such as inflammatory cytokines and biliary acids. The MRP2 levels and activity can also be affected by a large panel of xenobiotics, including chemopreventive agents and ligands of the pregnane X receptor, which may be a potential source of drug-drug interactions and drug adverse effects. MRP2 appears therefore as one of the major drug efflux pumps of the organism, whose functional and regulatory features are important to consider, notably for drug disposition. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:104 / 114
页数:11
相关论文
共 165 条
[1]   Bile secretory function after warm hepatic ischemia-reperfusion injury in the rat [J].
Accatino, L ;
Pizarro, M ;
Solís, N ;
Arrese, M ;
Koenig, CS .
LIVER TRANSPLANTATION, 2003, 9 (11) :1199-1210
[2]   Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump [J].
Akita, H ;
Suzuki, H ;
Ito, K ;
Kinoshita, S ;
Sato, N ;
Takikawa, H ;
Sugiyama, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1511 (01) :7-16
[3]   Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance [J].
Annereau, JP ;
Szakacs, G ;
Tucker, CJ ;
Arciello, A ;
Cardarelli, C ;
Collins, J ;
Grissom, S ;
Zeeberg, BR ;
Reinhold, W ;
Weinstein, JN ;
Pommier, Y ;
Paules, RS ;
Gottesman, MM .
MOLECULAR PHARMACOLOGY, 2004, 66 (06) :1397-1405
[4]   Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats [J].
Arimori, K ;
Kuroki, N ;
Hidaka, M ;
Iwakiri, T ;
Yamasaki, K ;
Okumura, M ;
Ono, H ;
Takamura, N ;
Kikuchi, M ;
Nakano, M .
PHARMACEUTICAL RESEARCH, 2003, 20 (06) :910-917
[5]  
Arts HJG, 1999, CLIN CANCER RES, V5, P2798
[6]   Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats [J].
Asakura, E ;
Nakayama, H ;
Sugie, M ;
Zhao, YL ;
Nadai, M ;
Kitaichi, K ;
Shimizu, A ;
Miyoshi, M ;
Takagi, K ;
Takagi, K ;
Hasegawa, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (2-3) :333-339
[7]   Interleukin-1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance [J].
Assenat, E ;
Gerbal-Chaloin, S ;
Larrey, D ;
Saric, J ;
Fabre, JM ;
Maurel, P ;
Vilarem, MJ ;
Pascussi, JM .
HEPATOLOGY, 2004, 40 (04) :951-960
[8]   Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions [J].
Bakos, É ;
Evers, R ;
Sinkó, E ;
Váradi, A ;
Borst, P ;
Sarkadi, B .
MOLECULAR PHARMACOLOGY, 2000, 57 (04) :760-768
[9]   Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione [J].
Ballatori, N ;
Rebbeor, JF .
SEMINARS IN LIVER DISEASE, 1998, 18 (04) :377-387
[10]   The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours [J].
Bart, J ;
Hollema, H ;
Groen, HJM ;
de Vries, EGE ;
Hendrikse, NH ;
Sleijfer, DT ;
Wegman, TD ;
Vaalburg, W ;
van der Graaf, WTA .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (14) :2064-2070